MRNA Stock Jumps on Moderna Flu Vaccine and Cancer Vaccine Data: Is the mRNA Platform Rebound Real?
Key Takeaways Moderna (NASDAQ: MRNA) jumped more than 10% as investors reassessed the company’s mRNA vaccine and oncology pipeline. The rally was driven by two major catalysts: FDA advisers backing Moderna’s mRNA flu vaccine and strong five-year melanoma data from Moderna’s personalized cancer vaccine program with Merck. MRNA stock is now being valued less as … Read more